OncoMatch/Clinical Trials/NCT05858814
RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT
Is NCT05858814 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies RC1012 for acute myeloid leukemia.
Treatment: RC1012 — To evaluate the safety and tolerability of RC1012 injection infusion in AML Patients after Allo-HSCT
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: allogeneic hematopoietic stem cell transplant
The subject has received an allogeneic HSCT within 60-100 days
Cannot have received: organ transplant
Exception: except for HSCT
Persons who have previously received an organ transplant or are preparing to receive an organ transplant (except for HSCT).
Cannot have received: maintenance therapy after HSCT
Subject who has received other maintenance therapy drugs after HSCT or who wish to receive other maintenance therapy.
Lab requirements
Blood counts
hemoglobin ≥ 80 g/L or maintained by transfusion; ANC ≥ 1.5 x 10^9/L; platelet count ≥ 50 x 10^9/L or maintained by transfusion; INR ≤ 1.5x ULN; APTT ≤ 1.5x ULN
Kidney function
serum creatinine ≤ 1.5x ULN or creatinine clearance ≥ 60 ml/min
Liver function
AST ≤ 3x ULN; ALT ≤ 3x ULN; total bilirubin ≤ 1.5x ULN (≤ 3.0x ULN for Gilbert-Meulengracht syndrome, direct bilirubin ≤ 1.5x ULN)
Cardiac function
LVEF ≥ 45%
With appropriate organ function: AST ≤ 3x ULN; ALT ≤ 3x ULN; total bilirubin ≤ 1.5x ULN, unless the patient has documented Gilbert syndrome. Patients with Gilbert-Meulengracht syndrome with total bilirubin ≤ 3.0x ULN and direct bilirubin ≤ 1.5x ULN may be included; serum creatinine ≤ 1.5x ULN or a creatinine clearance ≥ 60 ml/min; hemoglobin ≥ 80 g/L or hemoglobin maintained at that level following transfusion; INR ≤ 1.5x ULN and APTT ≤ 1.5x ULN; ANC ≥ 1.5 x 10^9/L; platelet count ≥ 50 x 10^9/L or maintained by transfusion; LVEF ≥ 45%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05858814 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior organ transplant, maintenance therapy after HSCT disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages